drugset / Trial / NCT00894842
Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
Phase 2/3
Completed
120 enrolled
National Research Foundation, Singapore
Duke University · collabNational University of Singapore · collabSingapore Clinical Research Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether pregnenolone will demonstrate significant improvements in cognitive functioning and negative symptoms compared to patients receiving placebo.
Timeline
- Start
- 2009-06
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pregnenolone | Other / unclassified | 500 mg | — |